DURHAM, N.C., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX ), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, will present data demonstrating that treatment with the investigational therapy, brincidofovir (BCV), reduced the incidence and severity of human herpesvirus 6 (HHV-6) viremia in allogeneic hematopoietic cell transplant (allo-HCT) recipients. Results from this post-hoc analysis of the Phase 3 SUPPRESS trial will be presented Saturday, Feb. 23 at the Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR 2019 in Houston, Texas. “HHV-6 is a common viral infection and is a significant concern in transplant patients, particularly in cord blood and other high-risk transplant recipients. These types of transplant are associated with higher rates of HHV-6 reactivation following transplant. Because these patients are immunocompromised, the virus can lead to a number of life-threatening complicati...